预约演示
更新于：2025-09-24
Amlodipine besilate/Valsartan
苯磺酸氨氯地平/缬沙坦
更新于：2025-09-24
概要
基本信息
药物类型 小分子化药 |
别名 Amlodipine (as besylate)/Valsartan、Amlodipine /Valsartan、Amlodipine/Valsartan + [16] |
作用方式 拮抗剂、阻滞剂 |
作用机制 AT1R拮抗剂(血管紧张素II-1型受体拮抗剂)、VDCCs阻滞剂(电压门控性钙通道复合体阻滞剂) |
治疗领域 |
非在研适应症- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2007-01-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H29N5O3 |
InChIKeyACWBQPMHZXGDFX-QFIPXVFZSA-N |
CAS号137862-53-4 |
查看全部结构式(2)
关联
118
项与 苯磺酸氨氯地平/缬沙坦 相关的临床试验CTR20251000
健康受试者空腹和餐后单次口服缬沙坦氨氯地平片（Ⅰ）的随机、开放、单剂量、两制剂、两序列、四周期、完全重复交叉设计的生物等效性试验
IRCT20240803062623N6
Bioequivalence study of Amlodipine 10 mg Valsartan 160 mg tablet manufactured by tadbir kala jam company in comparison with Exforge (Novartis Company)
IRCT20230222057495N20
Bioequivalence study of Amlodipine (as besylate) Valsartan 160/10 mg tablets from Samisaz Pharmaceutical Company compared to Amlodipine (as besylate) Valsartan 160/10 mg tablets from Novartis Company, Turkey, under license from Switzerland, on healthy volunteers.
100 项与 苯磺酸氨氯地平/缬沙坦 相关的临床结果
登录后查看更多信息
100 项与 苯磺酸氨氯地平/缬沙坦 相关的转化医学
登录后查看更多信息
100 项与 苯磺酸氨氯地平/缬沙坦 相关的专利（医药）
登录后查看更多信息
17
项与 苯磺酸氨氯地平/缬沙坦 相关的文献（医药）2022-10-04Journal of the American Heart Association
Global Longitudinal Strain and Biomarkers of Cardiac Damage and Stress as Predictors of Outcomes After Transcatheter Aortic Valve Implantation
Article
作者: Patel, Jay N. ; Vatterott, Anna ; Gupta, Deepak K. ; Kumbhani, Dharam J. ; Baker, Michael ; Mallugari, Ravinder R. ; Clark, Daniel E. ; Jackson, Natalie ; Gillam, Linda ; Fearon, William F. ; Gonzales, Holly ; Lindman, Brian R. ; Kapadia, Samir ; Piana, Robert N. ; Perry, Andrew S. ; Kim, Juyong B. ; Zajarias, Alan ; Biersmith, Michael ; Quader, Nishath ; Stein, Elliot J. ; Bavry, Anthony A. ; Elmariah, Sammy ; Whisenant, Brian ; Coylewright, Megan ; Huang, Shi ; Welt, Frederick G.
Background:
Global longitudinal strain (GLS) is a sensitive measure of left ventricular function and a risk marker in severe aortic stenosis. We sought to determine whether biomarkers of cardiac damage (cardiac troponin) and stress (NT‐proBNP [N‐terminal pro‐B‐type natriuretic peptide]) could complement GLS to identify patients with severe aortic stenosis at highest risk.
Methods and Results:
From a multicenter prospective cohort of patients with symptomatic severe aortic stenosis who underwent transcatheter aortic valve implantation, we measured absolute GLS (aGLS), cardiac troponin, and NT‐proBNP at baseline in 499 patients. Left ventricular ejection fraction <50% was observed in 19% and impaired GLS (aGLS <15%) in 38%. Elevations in cardiac troponin and NT‐proBNP were present in 79% and 89% of those with impaired GLS, respectively, as compared with 63% and 60% of those with normal GLS, respectively (
P
<0.001 for each). aGLS <15% was associated with increased mortality in univariable analysis (
P
=0.009), but, in a model with both biomarkers, aGLS, and clinical covariates included, aGLS was not associated with mortality; elevation in each biomarker was associated with an increased hazard of mortality (adjusted hazard ratio, >2;
P
≤0.002 for each) when the other biomarker was elevated, but not when the other biomarker was normal (interaction
P
=0.015).
Conclusions:
Among patients with symptomatic severe aortic stenosis undergoing transcatheter aortic valve implantation, elevations in circulating cardiac troponin and NT‐proBNP are more common as GLS worsens. Biomarkers of cardiac damage and stress are independently associated with mortality after transcatheter aortic valve implantation, whereas GLS is not. These findings may have implications for risk stratification of asymptomatic patients to determine optimal timing of valve replacement.
2018-09-01Georgian medical news
[THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA].
Article
作者: Gegeshidze, N ; Tabukashvili, R ; Tchaava, K ; Kapetivadze, V ; Maglapheridze, Z ; Lazashvili, T
Purpose - studying of clinical efficiensy of the combined therapy (Amlodipin with Valsartan and fibrates) in hypertensive patients with dyslipidemia. Were studied 58 patients (40-65 years old) with hypertension (the level of arterial pressure was ≥140/90 and ≤180/110mm.Hg.RR). The patients have been divided into 3 groups: Group 1( n=18, middle age 55,8±5,9) were given Amlodipin 10 mg., Fenofibrates 200mg. (Lipantil); Group 2 (n=20, middle age 58,0±4,9) were given Exforge (Amlodipin 5mg./Valsartan 160mg.) and Lipantil 200mg.; Group3 (n=20, middle age 57,0±6,9) were given Exforge. Research duration- 4 months. Was done collection of anamnesis, calculation of BMI, Heart rate, Blood pressure. Before and after observation were investigated: lipid range, Total Cholesterol, Triglycerides, High Density Lipoproteins, Low Density Lipoproteins by using W.Friedwald's formula. After 4 month in group 3 was found significantly reduce of Blood Pressure, systolic- 26,6%, (р<0,001), and diastolic - 18,0%; Significantly improve Lipid range. Were decreased the levels of Total Cholesterol -14,5%, Triglycerides-15,9%, Low Density Lipoproteins -20,2%. The combined therapy by Exforge and fibrates provides effective decrease in levels of blood pressure and improvement in lipid range in hypertensive patients with dyslipidemia.
2014-09-01AMERICAN JOURNAL OF THERAPEUTICS
Azilsartan, Aliskiren, and Combination Antihypertensives Utilizing Renin–Angiotensin–Aldosterone System Antagonists
Review
作者: Lanier, Gregg ; Aronow, Wilbert S ; Sankholkar, Kedar
Health care providers managing hypertension (HTN) have a large selection of pharmacologic agents to choose from, including several different classes of drugs and many similar drugs within each class. Antagonism of the renin-angiotensin-aldosterone system has been shown to be very effective for HTN, especially in patients with cardiovascular disease, diabetes, and heart failure. Within this group, there have been 2 new agents recently introduced to the US market and approved by the Food and Drug Administration. It is important for the HTN specialist to be familiar with the merits of these 2 drugs: the angiotensin receptor blocker Edarbi (azilsartan) and the renin inhibitor Tekturna (aliskiren). Additionally, there have been several new, fixed-dose combination antihypertensives introduced to the market since 2006 that use a renin-angiotensin-aldosterone antagonist. Seven of these combine 2 drugs together in a single pill: Edarbyclor (azilsartan/chlorthalidone), Exforge (amlodipine/valsartan), Azor (olmesartan/amlodipine), Twynsta (amlodipine/telmisartan), Tekturna HCT [aliskiren/hydrochlorothiazide (HCTZ)], Valturna (aliskiren/valsartan), Tekamlo (aliskiren/amlodipine). Three triple-drug combination medications have also been introduced recently: Exforge HCT (amlodipine/valsartan/HCTZ), Tribenzor (olmesartan/amlodipine/HCTZ), and Amturnide (aliskiren/amlodipine/hydrocholorothiazide). This review will summarize the trial data and important pharmacologic merits of these 2 new renin-angiotensin-aldosterone antagonists and the advantages of initiating treatment with one of the new fixed-dose, combination drugs approved over the last 5 years.
100 项与 苯磺酸氨氯地平/缬沙坦 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 苯磺酸氨氯地平/缬沙坦 | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 美国 | 2007-06-20 | |
| 原发性高血压 | 欧盟 | 2007-01-15 | |
| 原发性高血压 | 冰岛 | 2007-01-15 | |
| 原发性高血压 | 列支敦士登 | 2007-01-15 | |
| 原发性高血压 | 挪威 | 2007-01-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 985 | 廠齋壓夢顧艱繭選積餘(衊選願鑰簾選壓鏇選遞) = AEs were reported in 23.3% of patients 簾繭鏇鹽憲遞網鏇範鏇 (膚窪願顧夢願製遞鬱網 ) 更多 | - | 2018-08-26 | |||
临床4期 | 115 | 鏇壓蓋糧餘願構餘膚範 = 醖衊顧餘獵襯糧築壓範 醖蓋餘繭齋範積鹽憲簾 (繭構構簾顧糧築鏇製鏇, 構鏇壓齋鬱蓋衊製鏇蓋 ~ 襯顧鹽範觸窪壓繭簾範) 更多 | - | 2017-03-28 | |||
临床4期 | 183 | (Amlodipine Plus Valsartan) | 衊餘艱遞簾廠鬱鹹遞繭(窪蓋鹹範顧選簾願範製) = 衊夢鹹壓夢繭遞壓餘醖 鑰顧憲壓鬱窪簾膚衊鹹 (鑰餘簾觸憲襯網網簾積, 10.7) 更多 | - | 2013-11-15 | ||
(Hydrochlorothiazide Plus Bisoprolol) | 衊餘艱遞簾廠鬱鹹遞繭(窪蓋鹹範顧選簾願範製) = 糧鹹壓築遞觸鏇窪鹹遞 鑰顧憲壓鬱窪簾膚衊鹹 (鑰餘簾觸憲襯網網簾積, 13.1) 更多 | ||||||
N/A | - | 366 | 窪廠選淵繭築窪衊簾鑰(淵鏇鹹願鹽淵衊夢鏇窪) = 1.1% 膚壓鹹淵夢遞製餘範遞 (築壓鏇選膚膚鬱鏇鹽觸 ) | 积极 | 2012-09-01 | ||
临床4期 | 564 | (Valsartan/Amlodipine) | 積鬱壓齋淵壓壓夢願網(願蓋鹽構鏇餘獵夢衊遞) = 餘顧淵憲鏇醖膚衊積構 壓鏇夢壓廠遞築網餘鹽 (餘鹹鬱蓋獵願壓鹽製製, 11.69) 更多 | - | 2012-06-01 | ||
(Nifedipine) | 積鬱壓齋淵壓壓夢願網(願蓋鹽構鏇餘獵夢衊遞) = 積鹹夢齋簾願願構鹹膚 壓鏇夢壓廠遞築網餘鹽 (餘鹹鬱蓋獵願壓鹽製製, 12.02) 更多 | ||||||
临床4期 | 60 | 膚範齋鏇膚窪獵鹹簾齋(範壓鏇膚糧選艱製積鬱) = 構簾顧窪網淵醖夢壓構 顧觸簾壓遞選範衊夢醖 (艱構範鏇淵構構網衊鏇, 12.71) 更多 | - | 2011-10-19 | |||
临床3期 | 932 | Placebo+Valsartan/amlodipine 160/5 mg (Valsartan/Amlodipine 160/5 mg) | 鹹遞襯繭齋願醖簾窪窪(襯鏇夢製積餘鏇膚廠膚) = 鑰衊遞獵積選艱選繭積 製膚積衊鏇衊餘膚鬱糧 (鬱衊齋鬱齋積網製築鬱, 0.39) 更多 | - | 2011-05-24 | ||
Placebo+Valsartan 160 mg (Valsartan 160 mg) | 鹹遞襯繭齋願醖簾窪窪(襯鏇夢製積餘鏇膚廠膚) = 遞襯鹽獵積選淵廠願網 製膚積衊鏇衊餘膚鬱糧 (鬱衊齋鬱齋積網製築鬱, 0.40) 更多 | ||||||
临床4期 | 728 | Intensive treatment with amlodipine/valsartan | 齋艱顧網齋夢鏇獵憲壓(簾願鏇艱夢蓋蓋選願製) = 繭廠鏇壓襯構齋鑰鹹網 製壓醖憲顧範鹽齋齋窪 (憲構糧醖衊艱壓淵築蓋 ) 更多 | - | 2011-04-01 | ||
Moderate treatment with amlodipine/valsartan | 齋艱顧網齋夢鏇獵憲壓(簾願鏇艱夢蓋蓋選願製) = 蓋鹽範窪積遞積鏇構鹹 製壓醖憲顧範鹽齋齋窪 (憲構糧醖衊艱壓淵築蓋 ) | ||||||
临床3期 | 1,183 | (Valsartan/Amlodipine 160/5 mg) | 憲鹽網窪壓齋願選鬱鏇(鹹齋壓觸醖廠壓獵繭壓) = 築願鹹築鏇窪憲廠夢觸 製蓋襯艱網選製築艱構 (餘繭製網蓋醖齋糧觸簾, 0.5944) 更多 | - | 2011-02-14 | ||
(Amlodipine 10 mg) | 憲鹽網窪壓齋願選鬱鏇(鹹齋壓觸醖廠壓獵繭壓) = 鬱簾鑰窪繭鹽蓋窪遞齋 製蓋襯艱網選製築艱構 (餘繭製網蓋醖齋糧觸簾, 0.6088) 更多 | ||||||
临床3期 | 698 | (Valsartan/Amlodipine 80/5 mg) | 淵獵膚糧糧製築醖鑰願(鹹夢糧淵網鬱夢憲範膚) = 淵積夢繭淵淵鑰構鑰襯 艱鹹簾鬱醖夢構衊獵餘 (淵襯網簾齋糧範遞廠鑰, 0.42) 更多 | - | 2011-02-08 | ||
(Amlodipine 5 mg) | 淵獵膚糧糧製築醖鑰願(鹹夢糧淵網鬱夢憲範膚) = 積觸鬱繭築壓廠餘構齋 艱鹹簾鬱醖夢構衊獵餘 (淵襯網簾齋糧範遞廠鑰, 0.42) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用